Swathi Namburi is an Oncology physician affiliated with Swedish Medical Center. OpenAlex indexes 41 publications with 617 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1221 Madison St
Ste 1020
Seattle, WA 981041380
Telephone
206-215-2658Provider last certified this registry record 7 Dec 2022.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- Janssen Scientific Affairs, LLCProgram year20251 payment
- ADC THERAPEUTICS AMERICA, INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.1%Thalidomide Analog18.1%Lenalidomide62%Revlimid24%Pomalyst14%Part D<11 patientsAntimetabolite14.8%Hydroxyurea100%Part D≥24 patients+ 1 more class in this area
Dermatology
20%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor20%Acyclovir100%Part D≥38 patientsAnti-infectives
11.8%Short-acting sulfonamides4.3%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor3.1%Valacyclovir100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical Outcomes from the Pooled Safety Analysis of CD19 Nex-T™ (BMS-986353), a Chimeric Antigen Receptor (CAR) T cell Therapy Manufactured Using a Next-Generation Process, in Severe Refractory Autoimmune Diseases: Results from Phase 1 Breakfree Studies
Biology of Blood and Marrow Transplantation
2026 - A Retrospective Study of Bloodless Administration of Cellular Therapy in a Community Medical Center in an Outpatient and Inpatient setting: Patient Characteristics and Outcomes
Biology of Blood and Marrow Transplantation
2026 - Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting
Journal of Geriatric Oncology
2026 - Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses
Clinical Lymphoma Myeloma & Leukemia
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Rod Oskouian, MD
Swedish Medical Center
Ralph Aye, MD
Swedish Medical Center
Kelly Paulson, MD, PhD
Swedish Medical Center
Christopher McGann, MD
Swedish Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”